Drawing for LBDNA

USPTO serial 79333601

LBDNA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CAPSHAW, DANIEL
Law office
TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with LBDNA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations, enzymes and DNA for the preparation of nucleic acid for scientific research; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for use in agri-biotechnology and nanotechnology; nucleic acids comprising natural and unnatural nucleotides for use in nanotechnology applications including data storage, data retrieval and computing; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for use in nanotechnology applications including data storage, data retrieval and computing; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for use in nanotechnology applications including data storage, data retrieval and computing; nucleic acid analogues with organic and inorganic chemicals for laboratory use in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for laboratory use in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for laboratory use in creating nanostructures and scaffolds; nucleic acids or nucleic acid analogues for labelling, imaging and sensing applications for scientific and research purposes; nucleic acids or nucleic acid analogues as smart materials for scientific and research purposes; two-dimensional and three-dimensional nucleic acids or nucleic acid analogues for creating nanostructures and scaffolds for scientific and research purposes; parts and fittings for all the aforesaid technologyACTIVE—
005Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffoldsACTIVE—
009Electronic components and applications including wires, semi-conductors including transistors, rectifiers, diodes including light emitting diodes and systems for energy storage such as batteries all comprising of nucleic acids or nucleic acid analogues; parts and fittings for all the aforesaid technologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 5, 2024FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 17, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 17, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 6, 2023OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 19, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 19, 2023OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 22, 2023ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jan 17, 2023MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 17, 2023MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 17, 2023ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 20, 2022RFNPREFUSAL PROCESSED BY IB—
Jun 28, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 27, 2022RFRRREFUSAL PROCESSED BY MPU—
Jun 11, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 10, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 7, 2022DOCKASSIGNED TO EXAMINER—
Feb 26, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 22, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 17, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance